300199 翰宇药业
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)22.339-25.968-50.642-25.9551.912
总资产报酬率 ROA (%)4.560-5.526-14.920-9.8580.777
投入资产回报率 ROIC (%)5.385-6.471-17.110-11.2470.873

边际利润分析
销售毛利率 (%)62.46357.09249.30677.33672.042
营业利润率 (%)29.128-27.344-117.646-52.6475.313
息税前利润/营业总收入 (%)38.589-8.212-89.442-37.66917.970
净利润/营业总收入 (%)26.303-30.514-119.486-52.8953.864

收益指标分析
经营活动净收益/利润总额(%)89.04372.55789.42659.104-701.260
价值变动净收益/利润总额(%)0.721-0.952-6.79024.0781,105.394
营业外收支净额/利润总额(%)-0.0500.6320.7040.539-16.096

偿债能力分析
流动比率 (X)0.4800.3250.4800.7081.553
速动比率 (X)0.3260.1580.3730.5421.342
资产负债率 (%)78.01880.15376.10164.08657.813
带息债务/全部投入资本 (%)70.74072.01468.75155.19549.725
股东权益/带息债务 (%)35.44831.93338.71772.94492.826
股东权益/负债合计 (%)27.51123.99830.42554.90470.167
利息保障倍数 (X)4.073-0.425-3.080-2.4681.342

营运能力分析
应收账款周转天数 (天)37.52972.623189.181148.743143.063
存货周转天数 (天)215.710278.077281.953391.397300.840